@Yale_CRIT -
Feb 21

Fed judge denies pediatric exclusivity to @Amgen's cinacalcet (Sensipar). Read new blog by Jeanie Kim @akapczynski & @jsross119 for how this decision lowers drug prices and preserves @US_FDA's ability to encourage clinically meaningful pediatric research https://t.co/SJGGrVgHVL https://t.co/v497VCMQxQ

@Yale_CRIT -
Feb 14

RT @gregggonsalves: .@ElsTorreele from @MSFAccess asks: What Would a Pro-Patient, Pro-Public Health Regulatory System Look Like? (and not j…

@Yale_CRIT -
Feb 6

A big win for clinical data #transparency! EMA says "clinical study reports are in principle publicly accessible" -- how will @US_FDA @ScottGottliebMD respond? https://t.co/Xf2WhhLKyh

@Yale_CRIT -
Feb 1

Seven Thoughts on History and Present Practices of #FDA by @DonLight @joel_lexchin #YaleCRIT17 -- "so that reforms are not just designed to return to an idealized past, but rather to address the longstanding practices of approving drugs with weak evidence" https://t.co/CVmYBynw7L https://t.co/3WvaZTrhQz

@Yale_CRIT -
Jan 16

RT @alex_egilman: Our study in @JAMAInternalMed showing potential ~$3.4 billion in Medicare Part D savings between 2012-2015 if @CMSGov req…

CRIT Program Mission Statement

To promote health by improving the integrity and transparency of biomedical and clinical research

About the CRIT Program

The Collaboration for Research Integrity and Transparency (CRIT) is an inter-disciplinary initiative launched in 2016 to enhance the quality and transparency of the research base for medical products. Through research, advocacy, and litigation, CRIT is focused on ensuring that the clinical evidence that supports and informs our understanding of the safety and effectiveness of pharmaceuticals, medical devices, and other medical products is accurate, comprehensive, accessible, and reliable. The lack of transparency and integrity in clinical research has had serious consequences for patient and clinicians. Current legal structures and research practices are not adequate and efforts to understand and improve clinical research transparency and reporting are needed.

By influencing stakeholders engaged in the clinical research process and in translating these findings for clinical care, CRIT will focus and magnify the impact of our and others’ scholarship, policy analysis and legal action, advancing the field of research integrity, open science, and informing public discourse.

CRIT aims to

  • Achieve a legal and regulatory environment that promotes rigorous clinical research and supports regulatory and clinical decisions that are grounded in high-quality research and accessible data and results.
  • Strengthen the integrity of research of medical products by ensuring that data is both rigorous and reliable, and by facilitating public access to and independent analysis of clinical trial data and results.
  • Conduct legal, public health and health policy research that identifies strengths and weakness of our existing system for facilitating evidence generation and transparency, and developing and evaluating alternative approaches
  • Provide the public and key policymakers with tools that enhance and facilitate open access to data, research results, and other relevant information about medical products.



Contact Katherine Lawton at [email protected] if you are interested in joining our email list 

Contact Us

For more information or to join our mailing list, contact Katherine Lawton, Program Coordinator, at [email protected] or call (203) 436-8420

Mailing Address:

c/o Yale Law School
Collaboration for Research Integrity & Transparency
157 Church Street 17th Floor
New Haven, CT 06510-2100


Follow us on Twitter

Like us on Facebook